Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HTD1801 in Delaying Renal Impairment in T2DM and CKD
NCT07496177Phase 2Recruiting
- Sponsor
- Institute of Medical Biotechnology, Chinese Academy of Medical Sciences
- Start
- Jul 2026
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic kidney disease (CKD) comparing HTD1801 with placebo (2 arms). Primary endpoint: Relative change in urine albumin-to-creatinine ratio from baseline at 12 weeks. Started Jul 2026; status: recruiting.
02
Drugs
berberine ursodeoxycholate
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT07496177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07496177.